OR WAIT null SECS
The HCPLive insomnia page is a comprehensive resource for clinical news and insights on sleeplessness. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for insomnia, and more.
June 01, 2024
Article
A study presented at SLEEP 2024 found persistent or progressive insomnia symptoms are linked to a greater depression risk than subthreshold cases with gradual improvement.
May 30, 2024
Announced on May 29, 2024, data from the MDD3001 trial indicate use of seltorexant was associated with meaningful improvements in depressive symptoms and sleep disturbances.
March 25, 2024
With limited CBTi-trained psychologists, investigators assessed the effectiveness of a self-guided digital CBTi as another option, so people don’t have to turn to pills.
March 19, 2024
More than half of the participants were identified as insomnia sleepers and nappers, two suboptimal sleep patterns linked with an increased risk of a chronic condition.
March 06, 2024
FDA issued a Complete Response Letter to Vanda Pharmaceuticals stating tasimelteon for treating insomnia cannot be approved in its current form due to identified deficiencies.
February 19, 2024
A new study found non-hospitalized COVID-19 survivors from a Vietnam general population had a 76.1% prevalence of insomnia, with 22.8% of respondents with insomnia scoring for severe insomnia.
February 09, 2024
Multivariable analyses found genetic predispositions to overall rheumatoid arthritis with decreased sleep duration, as well as a significant genetic association between seropositive rheumatoid arthritis and insomnia symptoms.
January 23, 2024
Male college students were found to consume more energy drinks than female college students, and they had a greater risk for a short sleep duration due to energy drink consumption.
January 19, 2024
A new study found critical components of CBT-I are cognitive restructuring, third-wave components, sleep restrictions, and stimulus control.
January 18, 2024
Investigators observed no change in Insomnia Severity Index scores from baseline to weeks 7 and 25 with CBT-1, trazodone, or placebo, suggesting these insomnia treatment options are not effective for patients undergoing hemodialysis.